Drugs › Estrogen Agonist/Antagonist
Brand name · Raloxifene hydrochloride
Evista: adverse event reports filed with FDA
7,458 reports list it as a suspect or interacting product, 2004–2026. Class: Estrogen Agonist/Antagonist. Also reported as Evista /01303201/.
- 7,458
- reports as suspect product
- 0% of all reports · about 332 a year
- 11
- reports, 12 months to June 2026
- 11 in the 12 months before
- 55.2%
- marked serious by the reporter
- 53.8% across the class
- 1.9%
- record death among outcomes, as reported
- 145 reports · not verified by FDA
Between January 2004 and June 2026, 7,458 adverse event reports received by FDA list the brand name Evista (raloxifene hydrochloride) as a suspect or interacting product. Reports that mention it only as a concomitant medication (6,191) are left out of every figure here.
In the 12 months to June 2026, 11 reports listed it, close to the 11 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Over its reporting history that is about 332 reports a year and 0% of the 20,646,523 reports in the database, and 58% of the reports for the estrogen Agonist/Antagonist class. How many people take it is not in the data, so a count is not a rate of occurrence.
The reactions recorded most often are body height decreased (6.4%), pain in extremity (6.2%) and muscle spasms (5.7%). A report can list several reactions, so shares add to more than 100%; 994 different terms appear across these reports. Body height decreased is recorded in 6.4% of these reports, with no counterpart in the median estrogen Agonist/Antagonist drug (0%).
55.2% of the reports are marked serious by the reporter (53.8% across the class); 1.9% record death among the outcomes and 19% record hospitalisation, as reported. 61.9% of the reports came from consumers, and the largest patient age group is 65 to 74 (18.9%). FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."
Reports by month, five years
Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.
By year received
2026 covers reports received through June 2026 only.
Reactions recorded in the reports
share of Evista reports recording the termmedian drug in estrogen agonist/antagonist
- Body height decreased6.4%476
- Pain in extremitypain in an arm or leg6.2%464
- Muscle spasmsmuscle cramps5.7%424
- Bone density decreased5.2%386
- Painpain, site not specified5.1%380
- Falla fall5.1%377
- Drug ineffectivethe medicine did not work as expected4.6%342
- Arthralgiajoint pain4.4%325
- Hot flusha hot flush4%301
- Dizzinesslight-headedness or unsteadiness3.6%267
- Deep vein thrombosisa blood clot in a deep vein3.5%259
- Pulmonary embolisma blood clot in the lung3.4%254
- Breast cancerbreast cancer3.3%245
- Nauseafeeling sick3%222
- Back painback pain2.9%219
- Arthritis2.7%199
- Feeling abnormalfeeling odd or not right2.6%195
- Thrombosis2.5%186
- Headachehead pain2.5%183
- Astheniaweakness or lack of energy2.3%168
- Cerebrovascular accidentstroke2.2%167
- Fatiguetiredness2.1%160
- Oedema peripheralswelling of the legs, ankles or hands2%152
- Fracturea broken bone2%150
- Osteoporosisthinning of the bones2%149
- Spinal fracturea broken bone in the spine1.9%140
- Dyspnoeashortness of breath1.8%137
- Malaisegeneral feeling of being unwell1.8%134
- Hip fracturea broken hip1.7%125
- Gait disturbancedifficulty walking1.6%121
Top 30 of 994 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 3 drugs in the estrogen agonist/antagonist class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Outcomes recorded
Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 12,848 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."
Patients and reporters
Patient age
Patient sex
Who reported
Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 71.8% of reports give the United States as the country of the event or reporter.
Reason for use recorded
| Indication as recorded (MedDRA) | Reports | Share |
|---|---|---|
| Osteoporosis | 2,829 | 37.9% |
| Osteopenia | 384 | 5.1% |
| Prophylaxis | 157 | 2.1% |
| Osteoporosis prophylaxis | 136 | 1.8% |
| Osteoporosis postmenopausal | 134 | 1.8% |
| Breast cancer | 58 | 0.8% |
The indication field is filled in by the reporter and is often blank; shares are of all 7,458 reports.
In context
| Measure | Evista | Estrogen Agonist/Antagonist | All reports |
|---|---|---|---|
| Reports as suspect product | 7,458 | 12,848 | 20,646,523 |
| Share of that pool | — | 58% | 0% |
| Reports, latest 12 months | 11 | — | 1,332,454 |
| Marked serious | 55.2% | 53.8% | 57.4% |
| Death recorded among outcomes, per 1,000 reports | 19 | 30 | 91 |
| Hospitalisation recorded, per 1,000 reports | 190 | 172 | 213 |
| Consumer-filed share | 61.9% | 56.1% | 45.8% |
| Top term, share of reports | Body height decreased 6.4% | median 0% | 0.1% |
Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."
Other drugs in the estrogen agonist/antagonist class
| Drug | Name type | Reports | Latest 12 months | Marked serious |
|---|---|---|---|---|
| Tamoxifen citrate | generic | 3,064 | 104 | 80% |
| Osphena | brand | 2,326 | 5 | 14.7% |
Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.
Questions about Evista reports
How many adverse event reports has FDA received for Evista?
7,458 reports list Evista as a suspect or interacting product in the openFDA FAERS release of 28 Sep 2026, covering reports received through June 2026. 11 of them arrived in the latest 12 months. Another 6,191 list it only as a concomitant medication.
What reactions are recorded in Evista reports?
body height decreased (6.4%), pain in extremity (6.2%), muscle spasms (5.7%), bone density decreased (5.2%) and pain (5.1%). These are MedDRA preferred terms coded from what the reporter described; a report can list several, and a term's presence is not a finding that Evista was responsible.
How serious are the reports?
55.2% are marked serious by the reporter. Among the outcomes recorded, 1.9% of reports include death and 19% include hospitalisation. FDA has not verified these outcomes and states that the reports "cannot be used to estimate the incidence" of the events.
Who files these reports?
consumer or non-health professional (61.9%), physician (24.6%) and not given (7.8%). Most reports reach FDA through the manufacturer, which must forward reports it receives.
Are reports for Evista rising?
11 reports in the 12 months to June 2026, close to the 11 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Counts also move with how many people take a product, its time on the market and publicity.
Do these reports show that Evista was responsible for these reactions?
No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event." The reaction may relate to the condition being treated, to other medicines, or to something else.
Is this a list of the side effects of Evista?
No. It is a count of what was reported to FDA. The adverse reactions observed in clinical studies are printed on the FDA-approved label, which a pharmacist or clinician can go through with you.
How do I report an adverse event?
Consumers and health professionals can report to FDA through MedWatch (Form FDA 3500 online, or 1-800-FDA-1088), or to the manufacturer, which must pass reports on. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Evista as a suspect or interacting product; reports listing it only as a concomitant medication (6,191) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.